Results 161 to 170 of about 25,216 (236)

Retrospective Cohort Analysis of Treatment Patterns, Survival, and Cost‐Effectiveness in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in Lower Austria (2018–2022)

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Background R/R DLBCL is an aggressive malignancy with limited treatment options. Novel immunotherapies have improved outcomes in selected clinical‐trial populations, but their effectiveness in real‐world settings remains unclear. Their substantial costs also pose challenges for healthcare systems.
Josef Singer, Sandra Gottsauner‐Wolf, Doris A. Behrens   +2 more
wiley   +1 more source

Cytomegalovirus Infection After Chimeric Antigen Receptor T-Cell Therapy or Bispecific Antibody Treatment for Hematologic Malignancies. [PDF]

Transpl Infect Dis
Han J, Lim SY, Hyung J, Cho H, Yoon DH, Kim SH.   +5 more
europepmc   +1 more source

Multiomic characterization of small cell lung cancer: Real‐world insights into therapeutic opportunities

Cancer, Volume 132, Issue 5, 1 March 2026.
NK, natural killer; STING, Stimulator of Interferon Genes; TCI, T‐cell inflamed. Abstract Background The dominant expression of lineage‐related transcription factors (TFs)—ASCL1, NEUROD1, POU2F3, and, controversially, YAP1—has enabled the classification of small cell lung cancer (SCLC) into distinct subtypes (SCLC‐A/N/P/Y, respectively).
Sonam Puri, Andrew Elliott, Abdul Rafeh Naqash, Hassan Abu Shukair, Kathleen C. Kerrigan, Shiven Patel, Andreas Seeber, Florian Kocher, Dipesh Uprety, Hirva Mamdani, Amit A. Kulkarni, Gilberto Lopes, Balazs Halmos, Hossein Borghaei, Wallace Akerley, Gabriel L. Sica, Stephen V. Liu, Trudy G. Oliver, Taofeek K. Owonikoko   +18 more
wiley   +1 more source

A Bispecific Antibody Blocking Both TSLP and IL-4Rα for the Treatment of Allergic Inflammatory Diseases. [PDF]

Cells
Yu M, Chen P, Jin Y, Huang S, Jiang H, Zhou F, Chiu ML, Zhang D.   +7 more
europepmc   +1 more source

Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy

Clinical and Translational Medicine, Volume 16, Issue 3, March 2026.
In an ageing and inflamed haematopoietic ecosystem, clonal haematopoiesis and chronic lymphocytic leukaemia may originate from shared or parallel stem cell clones. This interaction modulates the effects of targeted therapies and contributes to cytopenias, cardiovascular toxicity, therapy‐related myeloid neoplasms and Richter transformation.
Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

AK112 (PD-1/VEGF-a bispecific antibody) combined with chemotherapy in locally advanced pancreatic cancer: a case report. [PDF]

Front Oncol
Yan J, Dong H, Wu C, Gu H, Qi Z, Chen T, Hu B, Zhou H, Long J.   +8 more
europepmc   +1 more source

Ciliary Defects in Inherited Retinal Diseases

Advanced Genetics, Volume 7, Issue 1, March 2026.
The photoreceptor cilium is a specialized sensory organelle essential for vision. This review systematically summarizes the structural and functional defects of the cilium that lead to inherited retinal diseases (IRDs). It highlights key pathogenic genes, elucidates molecular mechanisms of degeneration, and evaluates emerging therapeutic strategies ...
Guizhi Guo, Lin Li, Jun Zhou, Jie Ran
wiley   +1 more source

Flat dose intravenous immunoglobulin primary infection prophylaxis in multiple myeloma patients on BCMA and GPRC5D bispecific antibody therapy: the Vanderbilt experience. [PDF]

Front Immunol
Marneni N, Lessans S, Dholaria B, Sengsayadeth S, Biltibo EA, Patel V, Bhaskar S, Jayani R, Mohan S, Kishtagari A, Morgan D, Oluwole OO, Savani BN, Kassim AA, Baljevic M.   +14 more
europepmc   +1 more source

The European CAR‐T map—Current status and future directions to improve access to CAR T‐cell therapy for hematologic malignancies

HemaSphere, Volume 10, Issue 3, March 2026.
Abstract Despite its great promise, implementation of CAR‐T therapy—a personalized, logistically complex, and expensive treatment—remains challenging, hampering patient access across and within countries. Since 2018, six products have been centrally approved in Europe (i.e., the European Economic Area; EU‐approved) for 15 hematologic malignancy ...
Elise R. A. Pennings, Frederick W. Thielen, Florence Broussais, Julio Delgado, Ulrich Jaeger, Carmen Sanges, Yolanda Cabrerizo, Lutgart Roux‐Opstaele, Caroline Dreuillet, Eglys Gonzalez‐Marcano, Olga Millán, Barbara Huber, Solène Clavreul, Natacha Bolaños, Samantha Nier, Jana Mihályová, Roman Hájek, Michaela Horňáková, Robin Doeswijk, Catherine Thieblemont, Michael Hudecek, Carin A. Uyl‐de Groot, Marie José Kersten   +22 more
wiley   +1 more source

Correction: Bispecific antibody for lung cancer: mechanisms and clinical insights. [PDF]

Front Immunol
Chen W, Zhou A, Zhou Y.
europepmc   +1 more source